SML1657
吉非替尼
≥98% (HPLC), powder, EGFR TK inhibitor
别名:
N-（3-氯-4-氟-苯基）-7-甲氧基-6-（3-吗啉-4-基丙氧基）喹唑啉-4-胺, ZD1839
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C22H24ClFN4O3
化学文摘社编号:
分子量:
446.90
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
吉非替尼, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
room temp
SMILES string
COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4
InChI
1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChI key
XGALLCVXEZPNRQ-UHFFFAOYSA-N
Gene Information
human ... EGFR(1956)
Application
吉非替尼已用于：
- 研究其在子宫内膜癌治疗中的有效应用
- 细胞增殖、细胞周期和细胞凋亡试验
- 细胞活力测定和集落形成试验
Biochem/physiol Actions
吉非替尼是一种选择性表皮生长因子受体酪氨酸激酶 (EGFR TK) 抑制剂。吉非替尼具有抗肿瘤活性，已被批准用于治疗非小细胞肺癌 (NSCLC)。
吉非替尼对 EGFR 酪氨酸激酶结构域中 ATP（三磷酸腺苷）结合站点的亲和力高于 ATP。因此，已知吉非替尼可抑制子宫内膜癌的进展。
吉非替尼对 EGFR 酪氨酸激酶结构域中 ATP（三磷酸腺苷）结合站点的亲和力高于 ATP。因此，已知吉非替尼可抑制子宫内膜癌的进展。
Still not finding the right product?
Explore all of our products under 吉非替尼
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Roy S Herbst et al.
The oncologist, 7 Suppl 4, 9-15 (2002-08-31)
Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less
P M Ellis et al.
Current oncology (Toronto, Ont.), 22(3), e183-e215 (2015-06-20)
This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients-unselected, selected, and molecularly selected-in three treatment settings: first line, second line, and maintenance. Ninety-six randomized controlled trials
The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma.
Qiu M, et al.
Cancer Research, 78(11), 2839-2851 (2018)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML1657-10MG | 04061832964119 |
| SML1657-50MG | 04061832964126 |